Intermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failure

Journal of Cardiovascular Pharmacology

Volumn 53, Issue 2, 2009, Pages 157-161

  Drakos, Stavros G ^a   Kanakakis, John V ^a   Nanas, Serafim ^a   Bonios, Michael ^a   Kaldara, Elisabeth ^a   Katsaros, Fotios ^a   Pantsios, Christos ^a   Nanas, John N ^a,b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NONE   (Greece)

Author keywords

Amiodarone; End stage heart failure; Intermittent inotropic agents

Indexed keywords

AMIODARONE; CREATININE; DOBUTAMINE; INOTROPIC AGENT; LEVOSIMENDAN; SODIUM; ANTIARRHYTHMIC AGENT; CARDIOTONIC AGENT; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG INTERMITTENT THERAPY; FEMALE; HEART FAILURE; HEART RIGHT ATRIUM PRESSURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; SODIUM BLOOD LEVEL; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE; CHRONIC DISEASE; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; CARDIOTONIC AGENTS; CHRONIC DISEASE; DOBUTAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE; HUMANS; HYDRAZONES; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIDAZINES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 65549140547     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31819846cd     Document Type: Article

References (33)

1. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1997;134: 44-54.
2. Brown A, Cleland JG. Influence of concomitant disease on patterns of hospitalisation in patients with heart failure discharged from Scottish hospitals in 1995. Eur Heart J. 1995;19:1063-1069.
3. Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J. 1997;133:703-712.
4. Stevenson LW. Clinical use of inotropic therapy for heart failure: looking backward or forward? Part II. Chronic inotropic therapy. Circulation. 2003;108:492-497.
5. Felker GM, O'Connor CM. Inotropic therapy for heart failure: an evidence-based approach. Am Heart J. 2001;142:393-401. (Pubitemid 32801622)
6. Young JB. Evolving concepts in the treatment of heart failure: should new inotropic agents carry promise or paranoia? Pharmacotherapy. 1996;16: 78S-84S.
7. Sasayama S. What do the newer inotropic drugs have to offer? Cardiovasc Drugs Ther. 1992;6:15-18.
8. Thackray S, Easthaugh J, Freemantle N, et al. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur J Heart Fail. 2002;4:515-529. (Pubitemid 36564973)
9. Nanas JN, Kontoyannis DA, Alexopoulos GP, et al. Long-term intermittent dobutamine infusion combined with oral amiodarone improves the survival of patients with severe congestive heart failure. Chest. 2001;119:1173-1178.
10. Nanas JN, Tsagalou EP, Kanakakis J, et al. Long-term intermittent dobutamine infusion, combined with oral amiodarone for end-stage heart failure: a randomized double-blind study. Chest. 2004;125:1198-1204. (Pubitemid 38501329)
11. Rose EA, Gelijns AC, Moskowitz AJ, et al. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med. 2001;345: 1435-1443.
12. Drakos SG, Charitos EI, Nanas SN, et al. Ventricular-assist devices for the treatment of chronic heart failure. Expert Rev Cardiovasc Ther. 2007;5: 571-584. (Pubitemid 46805583)
13. DiAmico CL. Patient selection in the current era. J Cardiovasc Nurs. 2005;20:S4-S13
14. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2005;112: e154-e235.
15. DICE Collaborative Group. Ambulatory intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial. J Am Coll Cardiol. 1997;29:326A.
16. Dies F, Krell MJ, Whitlow P. Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure [abstract]. Circulation. 1986;74 (Suppl II):38.
17. Elis A, Bental T, Kimchi O, et al. Intermittent dobutamine treatment in patients with chronic refractory congestive heart failure: a randomized, double-blind, placebo-controlled study. Clin Pharmacol Ther. 1998;63: 682-685. (Pubitemid 28327896)
18. Erlemeier HH, KupperW, BleifeldW. Intermittent infusion of dobutamine in the therapy of severe congestive heart failure-long-term effects and lack of tolerance. Cardiovasc Drugs Ther. 1992;6:391-398.
19. Nanas JN, Papazoglou P, Tsagalou EP, et al. Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone. Am J Cardiol. 2005;95:768-771. (Pubitemid 40332658)
20. Nanas JN, Papazoglou PP, Terrovitis JV, et al. Hemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone. Am J Cardiol. 2004;94:1329-1332. (Pubitemid 39469964)
21. Nanas JN, Tsagalou EP, Nanas SN, et al. Reverse left ventricular remodeling by intermittent dobutamine infusions and amiodarone in end-stage heart failure due to idiopathic dilated cardiomyopathy. Int J Cardiol. 2006;108:237-243.
22. Tsagalou EP, Anastasiou-Nana MI, Terrovitis JV, et al. The long-term survival benefit conferred by intermittent dobutamine infusions and oral amiodarone is greater in patients with idiopathic dilated cardiomyopathy than with ischemic heart disease. Int J Cardiol. 2006;108:244-250.
23. Drakos S, Bonios M, Tsagalou E, et al. Chronic intermittent inotropic infusions combined with prophylactic oral amiodarone for end-stage heart failure patients. J Card Fail. 2006;12:337.
24. Shakar SF, Abraham WT, Gilbert EM, et al. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol. 1998;31:1336-1340. (Pubitemid 128713123)
25. Greene HL. The CASCADE Study: randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle; the CASCADE Investigators. Am J Cardiol. 1993;72:70F-74F.
26. Kudenchuk PJ, Cobb LA, Copass MK, et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med. 1999;341:871-878. (Pubitemid 29427049)
27. Adamopoulos S, Piepoli M, Qiang F, et al. Effects of pulsed-stimulant therapy on b-adrenoceptors and chronotropic responsiveness in chronic heart failure. Lancet. 1995;345:344-349.
28. Leier CV, Binkley PF. Parenteral inotropic support for advanced congestive heart failure. Prog Cardiovasc Dis. 1998;41:207-224. (Pubitemid 29009200)
29. Unverferth DV, Magorien RD, Altschuld R, et al. The hemodynamic and metabolic advantages gained by a three-day infusion of dobutamine in patients with congestive cardiomyopathy. Am Heart J. 1983;106:29-34.
30. Binkley PF, Van Fossen DB, Nunziata E, et al. Influence of positive inotropic therapy on pulsatile hydraulic load and ventricular-vascular coupling in congestive heart failure. J Am Coll Cardiol. 1990;15: 1127-1135. (Pubitemid 20104574)
31. Unverferth DV, Magorien RD, Lewis RP, et al. Long-term benefit of dobutamine in patients with congestive cardiomyopathy. Am Heart J. 1980;100:622-630. (Pubitemid 11226039)
32. Mebazaa A, Nieminen MS, Packer M, et al; SURVIVE Investigators. Levosimendan vs. dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007;297: 1883-1891.
33. Bardy GH, Lee KL, Mark DB, et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005; 352:225-237.